NEW ORLEANS — Weekly petrelintide demonstrated clinically meaningful weight loss through 42 weeks and was well tolerated among adults with obesity or overweight without diabetes, according to results from the phase 2 ZUPREME-1 trial.
Petrelintide (Roche/Zealand Pharma) is a long-acting human amylin analog that is being investigated as a once-weekly injectable medication for obesity. Petrelintide binds to different cell types than GLP-1, W. Timothy Garvey, MD, FACE, MABOM, endocrinologist and professor at the University of Alabama (UAB) at Birmingham and principal investigator of the UAB

NEW ORLEANS —A once-weekly combination therapy of cagrilintide and semaglutide reduced HbA1c and body weight across a wide range of adults with type 2 diabetes, according to data from three phase 3 trials.
CagriSema (Novo Nordisk) is a combination drug consisting of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide (Ozempic/Wegovy). During a presentation at the American Diabetes Association Scientific Sessions, researchers presented findings from the REIMAGINE 1, 2 and 3 trials that showed CagriSema can benefit adults with type 2 diabetes who were

Nearly half of patients with psoriasis screened for cardiovascular disease risk factors at the recommendation of their dermatologist had elevated blood pressure, cholesterol or HbA1c, suggesting a need for improved care coordination.
The findings, presented in a poster during the Society for Investigative Dermatology Annual Meeting, also showed people with psoriasis want to engage in proactive measures that will reduce their disease burden, according to Joel M. Gelfand, MD, MSCE, FAAD, Healio Dermatology’s Chief Medical Editor and one of the study’s co-authors.
“About 80% of patients completed

Fungal keratitis is an infectious corneal disease. Its most common risk factor is trauma with vegetative matter.
The usual presentation is characterized by fluffy white corneal ulceration with satellite lesions and a hypopyon. Other manifestations include endothelial plaque and scleral or anterior chamber involvement. Endothelial abscess is not only a rare presentation, but it presents treatment challenges due to non-penetration of topical medications across the stroma. Although latent infections are more common with organisms such as Mycobacteriumtuberculosis and Herpesviridae, such a

A 42-year-old man with no significant medical history was urgently referred to New England Eye Center in July 2025 for 6 weeks of central vision loss in the left eye and left optic disc edema.
In May 2025, he noticed a sudden, painless central vision loss in the left eye upon waking up. He did not have any associated symptoms. He initially thought the change in vision was secondary to a refractive error and saw his local optometrist. He was referred for a retina evaluation for possible central serous chorioretinopathy. Because he was told the condition could resolve in a couple of weeks, he

A novel NLRP3 inhibitor reduced high-sensitivity C-reactive protein and other inflammatory biomarkers in patients at high inflammatory risk, according to the results of a trial presented at the European Atherosclerosis Society Congress.
The NLRP3 inhibitor, ruvonoflast (NodThera), “is designed to directly inhibit activation of the NLRP3 inflammasome in multiple clinically relevant cell types (eg, macrophages, vascular cells),” Jyothis P. George, MD, PhD, chief medical officer of NodThera and an author of the study, told Healio. “By targeting NLRP3, ruvonoflast aims to reduce the production of

A 39-item questionnaire predicts difficult-to-treat depression, enabling identification of patients at risk for treatment failure, according to an abstract presented at the American Psychiatric Association Annual Meeting in San Francisco.
Difficult-to-treat depression is not the same thing as treatment-resistant depression, Mark Zimmerman, MD, chief of psychiatry and behavioral health, South County Psychiatry, said during his presentation.
“Most commonly,” Zimmerman said, treatment-resistant depression is “defined as failing two or more treatment trials during the current episode.”
Introduced

A kidney transplant risk prediction model demonstrated accuracy at 10 years for predicting mortality risks, according to study data published in JAMA Network Open.
Previous studies that developed kidney transplant risk prediction models were limited by a lack of external validation cohorts and short follow-up periods, according to Charlotte Debiais-Deschamps, MD, a nephrologist at the Assistance Publique-Hôpitaux de Paris, and colleagues. Thus, the researchers aimed to develop a risk prediction model that could predict both short-term and long-term mortality risks for kidney transplant

A combined death rate from alcohol, substance use and suicide in the U.S. decreased in 2024, but whether this progress will continue depends on sustained public health investments, according to a Trust for America’s Health, or TFAH, report.
The decrease builds upon a 4% reduction in these deaths in 2023, according to a press release.
“After decades of alarming increases, we are finally starting to see some steady progress in the effort to reduce deaths from alcohol, drug overdoses and suicide,” TFAH President and CEO J. Nadine Gracia, MD, MSCE, said during a press briefing. “This is positive

ORLANDO — In patients newly diagnosed with Mycobacterium avium complex lung disease, amikacin liposome inhalation suspension Arikayce plus multidrug therapy for 12 months improved respiratory symptoms, according to results presented here.
“Not only did this regimen improve the quality of life of the participants, but it made a significant microbiologic impact as well,” Charles L. Daley, MD, chief of the division of mycobacterial and respiratory infections at National Jewish Health, said during his presentation at the American Thoracic Society International Conference.
In the multinational,